Short term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomised controlled trial

详细信息    查看全文

• 作者：Louise Ganderton (1) (2) (3)
  Sue Jenkins (1) (3) (4)
  Kevin Gain (1) (2) (5)
  Robin Fowler (1) (2) (3)
  Peta Winship (2)
  Dianne Lunt (2)
  Eli Gabbay (1) (2) (3) (5) (6)
  
• 刊名：BMC Pulmonary Medicine
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：11
• 期：1
• 全文大小：286KB
• 参考文献：1. Desai S, Channick R: Exercise in patients with pulmonary arterial hypertension. / J Cardiopulm Rehabil Prev 2008, 28:12鈥?6.
  2. Schannwell C, Steiner S, Strauer B: Diagnostics in pulmonary hypertension. / J Physiol Pharmacol 2007,58(Suppl. 5):591鈥?02.
  3. Gabbay E, Reed A, Williams T: Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. / Int Med J 2007, 37:38鈥?8. CrossRef
  4. Rubin L: Primary pulmonary hypertension. / N Engl J Med 1997,336(2):111鈥?19. CrossRef
  5. Arena R, Lavie C, Milani R, Myers J, Guazzi M: Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: An evidence-based review. / J Heart Lung Transplant 2010,29(2):159鈥?73. CrossRef
  6. Sun X, Hansen J, Oudiz R, Wasserman K: Exercise pathophysiology in patients with primary pulmonary hypertension. / Circulation 2001, 104:429鈥?35. CrossRef
  7. Naeije R: Breathing more with weaker respiratory muscles in pulmonary arterial hypertension. / Eur Respir J 2005, 25:6鈥?. CrossRef
  8. Bauer R, Dehnert C, Schoene P, Filusch A, B盲rtsch P, Borst M, Katus H, Meyer F: Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. / Respir Med 2007, 101:2366鈥?369. CrossRef
  9. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S: Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. / Thorax 2010, 65:113鈥?17. CrossRef
  10. de Man F, Handoko M, Groepenhoff H, van 't Hul A, Abbink J, Koppers R, Grotjohan H, Twisk J, Bogaard H, Boonstra A, Postmus PE, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A: Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. / Eur Respir J 2009, 34:669鈥?75. CrossRef
  11. Meyer F, Lossnitzer D, Kristen A, Schoene A, K眉bler W, Katus H, Borst M: Respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension. / Eur Respir J 2005, 25:125鈥?30. CrossRef
  12. Kabitz H, Schwoerer A, Bremer H, Sonntag F, Walterspacher S, Walker D, Schaefer V, Ehlken N, Staehler G, Halank M, Klose H, Ghofrani HA, Hoeper MM, Gr眉nig E, Windisch W: Impairment of respiratory muscle function in pulmonary hypertension. / Clin Sci 2008, 114:165鈥?71. CrossRef
  13. Velez-Roa S, Ciarka A, Najem B, Vachiery J, Naeije R, van de Borne P: Increased sympathetic nerve activity in pulmonary artery hypertension. / Circulation 2004,110(10):1308鈥?312. CrossRef
  14. McLaughlin V, Archer S, Badesch D, Barst R, Farber H, Lindner J, Mathier M, McGoon M, Park M, Rosenson R, Rubin LJ, Tapson VF, Varga J: ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association. / J Am Coll Cardiol 2009,53(17):1573鈥?619. CrossRef
  15. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper M, Halank M, Meyer F, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth F, Wilkens H, Katus HA, Olschewski H, Gr眉nig E: Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. / Circulation 2006, 114:1482鈥?489. CrossRef
  16. Belardinelli R, Georgiou D, Cianci G, Purcaro A: Randomised controlled trial of long-term moderate exercise training in chronic heart failure. / Circulation 1999, 99:1173鈥?182.
  17. Maiorana A, O'Driscoll G, Cheetham C, Collis J, Goodman C, Rankin S, Taylor R, Green D: Combined aerobic and resistance exercise training improves functional capacity and strength in CHF. / J Appl Physiol 2000,88(5):1565鈥?570.
  18. Pi帽a I, Apstein C, Balady G, Belardinelli R, Chaitman B, Duscha B, Fletcher B, Fleg J, Myers J, Sullivan M: Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. / Circulation 2003, 107:1210鈥?225. CrossRef
  19. Rees K, Taylor R, Singh S, Coats A, Ebrahim S: Exercise based rehabilitation for heart failure (review). / Cochrane Database Syst Rev 2004., (3): Art. No. CD003331. DOI:10.1002/14651858.CD003331.pub2
  20. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. / Am J Respir Crit Care Med 2006,173(12):1390鈥?413. CrossRef
  21. Troosters T, Casaburi R, Gosselink R, Decramer M: Pulmonary rehabilitation in chronic obstructive pulmonary disease. / Am J Respir Crit Care Med 2005, 172:19鈥?8. CrossRef
  22. Ries A, Bauldoff G, Carlin B, Casaburi R, Emery C, Mahler D, Make B, Rochester C, ZuWallack R, Herrerias C: Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. / Chest 2007,131(Suppl. 5):4鈥?2. CrossRef
  23. Lacasse Y, Goldstein R, Lasserson T, Martin S: Pulmonary rehabilitation for chronic obstructive pulmonary disease. / Cochrane Database Syst Rev 2006., (4): Art. No.CD003793. DOI:10.1002/14651858.CD003793.pub2
  24. Shoemaker M, Wilt J, Dasgupta R, Oudiz R: Exercise training in patients with pulmonary arterial hypertension: a case report. / Cardiopulm Phys Ther J 2009,20(4):12鈥?8.
  25. Uchi M, Saji T, Harada T: Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy. / J Cardiol 2005, 46:183鈥?93.
  26. Pulmonary rehabilitation toolkit [http://www.pulmonaryrehab.com.au/welcome.asp]
  27. Recommended framework for cardiac rehabilitation '04 [http://www.heartfoundation.org.au/SiteCollectionDocuments/Recommended-framework.pdf]
  28. Moher M, Schultz K, Altman D: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. / Lancet 2001, 357:1191鈥?194. CrossRef
  29. Beller E, Gebski V, Keech A: Randomisation in clinical trials. / Med J Aust 2002, 177:565鈥?67.
  30. Wasserman K, Hansen J, Sue D, Stringer W, Whipp B: Clinical exercise testing. In / Principles of exercise testing and interpretation. 4th edition. Philadelphia: Lippincott Williams and Wilkins; 2005:133鈥?60.
  31. Borg G: Psychophysical bases of perceived exertion. / Med Sci Sports Exerc 1982, 14:377鈥?81.
  32. McKenna S, Doughty N, Meads D, Doward L, Pepke-Zaba J: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension. / Qual Life Res 2006, 15:103鈥?15. CrossRef
  33. Ganderton L, Gabbay E, Fowler R, Gain K, McKenna S, Jenkins S: Validation of the Cambridge Pulmonary Hypertension Outcome Review for an Australian and New Zealand PAH population [abstract]. / Respirology 2009,14(Suppl. 1):A69.
  34. Hawthorne G, Osborne R, Taylor A, Sansoni J: The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. / Qual Life Res 2007, 16:661鈥?73. CrossRef
  35. Booth M: Assessment of physical activity: an international perspective. / Res Q Exerc Sport 2000,71(2):s114鈥?20.
  36. American Thoracic Society/American College of Chest Physicians: ATS/ACCP statement on cardiopulmonary exercise testing. / Am J Respir Crit Care Med 2003, 167:211鈥?77. CrossRef
  37. Fox S, Naughton J, Haskell W: Physical activity and the prevention of coronary heart disease. / Ann Clin Res 1971,1(3):404鈥?32.
  38. Gali猫 N, Olschewski H, Oudiz R, Torres F, Frost A, Ghofrani H, Badesch D, McGoon M, McLaughlin V, Roecker E, Gerber MJ, Dufton C, Wiens BL, Rubin LJ: Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. / Circulation 2008, 117:3010鈥?019. CrossRef
  39. Ghofrani H, Wilkins M, Rich S: Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. / Circulation 2008, 118:1195鈥?201. CrossRef
  40. Myers J: Principles of exercise prescription for patients with chronic heart failure. / Heart Fail Rev 2007, 13:61鈥?8. CrossRef
  41. Lachin J: Statistical considerations in the intention-to-treat principle. / Control Clin Trials 2000, 21:167鈥?89. CrossRef
  42. Berger V, Exner D: Detecting selection bias in randomized clinical trials. / Control Clin Trials 1999, 20:319鈥?27. CrossRef
  43. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/11/25/prepub
  
• 作者单位：Louise Ganderton (1) (2) (3)
  Sue Jenkins (1) (3) (4)
  Kevin Gain (1) (2) (5)
  Robin Fowler (1) (2) (3)
  Peta Winship (2)
  Dianne Lunt (2)
  Eli Gabbay (1) (2) (3) (5) (6)
  
  1. School of Physiotherapy and Curtin Health Innovation Research Institute, Curtin University, Perth, Australia
  2. Royal Perth Hospital, Perth, Australia
  3. Lung Institute of Western Australia, Centre for Asthma, Allergy and Respiratory Research, University of Western Australia, Perth, Australia
  4. Sir Charles Gairdner Hospital, Perth, Australia
  5. School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
  6. School of Medicine, University of Notre Dame, Fremantle, Australia
  

文摘

Background Advances in the understanding and management of pulmonary arterial hypertension have enabled earlier diagnosis and improved prognosis. However, despite best available therapy, symptoms of exertional dyspnoea and fatigue are commonly reported and result in a reduced capacity to perform daily activities and impaired quality of life. Exercise training has demonstrated efficacy in individuals with other respiratory and cardiovascular diseases. Historically, however, exercise training has not been utilised as a form of therapy in pulmonary arterial hypertension due to the perceived risk of sudden cardiac death and the theoretical possibility that exercise would lead to worsening pulmonary vascular haemodynamics and deterioration in right heart function. Now, with the advances in pharmaceutical management, determining the safety and benefits of exercise training in this population has become more relevant. Only three studies of supervised exercise training in pulmonary arterial hypertension have been published. These studies demonstrated improvements in exercise capacity and quality of life, in the absence of adverse events or clinical deterioration. However, these studies have not utilised an outpatient-based, whole body exercise training program, the most common format for exercise programs within Australia. It is uncertain whether this form of training is beneficial and capable of producing sustained benefits in exercise capacity and quality of life in this population. Design/Methods This randomised controlled trial will determine whether a 12 week, outpatient-based, supervised, whole body exercise training program, followed by a home-based exercise program, is safe and improves exercise capacity and quality of life in individuals with pulmonary arterial hypertension. This study aims to recruit 34 subjects who will be randomly allocated to the exercise group (supervised exercise training 3 times a week for 12 weeks, followed by 3 sessions per week of home exercise for 12 weeks) or the control group (usual medical care). Subjects will be assessed at baseline, 12 weeks and 24 weeks. Discussion This study will determine whether outpatient-based, whole body exercise training is beneficial and safe in individuals with pulmonary arterial hypertension. Additionally, this study will contribute to clinical practice guidelines for this patient population. Trial registration Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12609000502235